[go: up one dir, main page]

SMT201700054B - Porzioni leganti anti-c5a con elevata attività bloccante - Google Patents

Porzioni leganti anti-c5a con elevata attività bloccante

Info

Publication number
SMT201700054B
SMT201700054B SM201700054T SM201700054T SMT201700054B SM T201700054 B SMT201700054 B SM T201700054B SM 201700054 T SM201700054 T SM 201700054T SM 201700054 T SM201700054 T SM 201700054T SM T201700054 B SMT201700054 B SM T201700054B
Authority
SM
San Marino
Prior art keywords
binding portions
blocking activity
high blocking
activity
binding
Prior art date
Application number
SM201700054T
Other languages
English (en)
Inventor
Renfeng Guo
Niels Christoph Riedemann
Yan Li
Beifen Shen
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41683202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201700054(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Publication of SMT201700054B publication Critical patent/SMT201700054B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
SM201700054T 2009-11-26 2017-01-24 Porzioni leganti anti-c5a con elevata attività bloccante SMT201700054B (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26469609P 2009-11-26 2009-11-26
EP09014745A EP2327725A1 (en) 2009-11-26 2009-11-26 Anti-C5a binding moieties with high blocking activity
PCT/EP2010/007197 WO2011063980A1 (en) 2009-11-26 2010-11-26 Anti-c5a binding moieties with high blocking activity
EP10782561.4A EP2504362B1 (en) 2009-11-26 2010-11-26 Anti-c5a binding moieties with high blocking activity

Publications (1)

Publication Number Publication Date
SMT201700054B true SMT201700054B (it) 2017-03-08

Family

ID=41683202

Family Applications (3)

Application Number Title Priority Date Filing Date
SM20200106T SMT202000106T1 (it) 2009-11-26 2010-11-26 Porzioni leganti anti-c5a con elevata attivita' bloccante
SM20170054T SMT201700054T1 (it) 2009-11-26 2010-11-26 Porzioni leganti anti-c5a con elevata attività bloccante
SM201700054T SMT201700054B (it) 2009-11-26 2017-01-24 Porzioni leganti anti-c5a con elevata attività bloccante

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SM20200106T SMT202000106T1 (it) 2009-11-26 2010-11-26 Porzioni leganti anti-c5a con elevata attivita' bloccante
SM20170054T SMT201700054T1 (it) 2009-11-26 2010-11-26 Porzioni leganti anti-c5a con elevata attività bloccante

Country Status (29)

Country Link
US (4) US8802096B2 (it)
EP (4) EP2327725A1 (it)
JP (4) JP6104605B2 (it)
KR (3) KR101844611B1 (it)
CN (2) CN102741283B (it)
AU (1) AU2010324141B2 (it)
BR (1) BR112012012514B1 (it)
CA (1) CA2780520C (it)
CL (1) CL2012001304A1 (it)
CY (2) CY1118463T1 (it)
DK (2) DK2504362T3 (it)
EA (1) EA022759B1 (it)
ES (2) ES2773725T3 (it)
FR (1) FR25C1024I1 (it)
HR (2) HRP20170041T1 (it)
HU (2) HUE032543T2 (it)
IL (1) IL219911A (it)
LT (2) LT3181582T (it)
MX (1) MX2012006060A (it)
NL (1) NL301334I2 (it)
NZ (1) NZ600348A (it)
PE (1) PE20130314A1 (it)
PH (1) PH12012501243A1 (it)
PL (2) PL2504362T3 (it)
PT (2) PT2504362T (it)
RS (2) RS59955B1 (it)
SI (2) SI3181582T1 (it)
SM (3) SMT202000106T1 (it)
WO (1) WO2011063980A1 (it)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8703129B2 (en) 2008-09-07 2014-04-22 GlycoNex, Inc. Antibodies against extended type 1 chain antigens, derivatives thereof and use
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
EP2563813B1 (en) 2010-04-30 2015-08-26 Alexion Pharmaceuticals, Inc. Anti-c5a antibodies and methods for using the antibodies
BR112013013354A2 (pt) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
JP6618682B2 (ja) 2011-06-22 2019-12-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体阻害剤による慢性障害の治療方法
RS58503B1 (sr) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
LT3038633T (lt) 2013-08-28 2021-03-25 Ipc Research, Llc Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CN106132982A (zh) * 2014-03-20 2016-11-16 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂
EA035979B1 (ru) 2014-09-09 2020-09-08 Янссен Байотек, Инк. Варианты комбинированной терапии анти-cd38 антителами
KR102597989B1 (ko) 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
IL319936A (en) 2015-05-20 2025-05-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP4516319A3 (en) 2015-11-03 2025-05-07 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
WO2017196960A1 (en) * 2016-05-10 2017-11-16 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
MY196006A (en) 2016-06-14 2023-03-06 Regeneron Pharma Anti-C5 Antibodies and Uses Thereof
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
MX2019010574A (es) * 2017-03-06 2020-01-15 Univ Pennsylvania Anticuerpos anti-c5 y su uso.
MX2019011252A (es) * 2017-03-23 2020-01-23 Univ Pennsylvania Anticuerpos anti-c5a y usos de los mismos.
IL261809B2 (en) * 2017-04-03 2024-04-01 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5A activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
CA3066689C (en) 2017-06-23 2024-01-16 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
KR20200098528A (ko) 2017-12-13 2020-08-20 리제너론 파아마슈티컬스, 인크. 항-c5 항체 조합물 및 이의 용도
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
EP3846850A4 (en) 2018-09-06 2022-06-15 The Trustees of the University of Pennsylvania HUMANIZED ANTI-C5 ANTIBODIES AND USES THEREOF
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
EP4126222A1 (en) * 2020-03-27 2023-02-08 InflaRx GmbH Inhibitors of c5a for the treatment of corona virus infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
JP7674399B2 (ja) * 2020-06-24 2025-05-09 スタイドソン・（ベイジン）・バイオファーマシューティカルズ・カンパニー・リミテッド Ｃ５ａを特異的に認識する抗体およびその使用
KR20230142831A (ko) 2021-01-13 2023-10-11 비스테라, 인크. 인간화된 보체 5a 수용체 1 항체 및 이의 사용 방법
WO2023050233A1 (en) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Humanized anti-c5a antibodies and uses thereof
CN116670288A (zh) * 2021-12-22 2023-08-29 舒泰神（北京）生物制药股份有限公司 一种分离的抗C5a抗体及其制剂与应用
CN117203230A (zh) * 2022-04-02 2023-12-08 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用
WO2024245527A1 (en) 2023-05-26 2024-12-05 Inflarx Gmbh Treatment of pneumonia and ards with inhibitors of c5a and il-6 activity
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
TW202535938A (zh) 2023-10-17 2025-09-16 德商拜恩迪克公司 專一性結合ｃｄ３之抗原結合蛋白及其醫藥用途
WO2025082594A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1878441B1 (en) * 2001-08-17 2018-01-24 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
CN100391537C (zh) * 2001-08-17 2008-06-04 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
EP2270049A3 (en) * 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
EP2563813B1 (en) 2010-04-30 2015-08-26 Alexion Pharmaceuticals, Inc. Anti-c5a antibodies and methods for using the antibodies

Also Published As

Publication number Publication date
HRP20170041T1 (hr) 2017-03-10
PE20130314A1 (es) 2013-04-03
US9073983B2 (en) 2015-07-07
KR101844611B1 (ko) 2018-04-02
KR102112969B1 (ko) 2020-05-19
PL2504362T3 (pl) 2017-08-31
EP2327725A1 (en) 2011-06-01
CA2780520C (en) 2021-11-23
EA022759B1 (ru) 2016-02-29
FR25C1024I1 (fr) 2025-08-01
EP3181582A1 (en) 2017-06-21
IL219911A (en) 2017-03-30
US20120231008A1 (en) 2012-09-13
EP3181582B1 (en) 2020-01-29
JP6104605B2 (ja) 2017-03-29
PH12012501243A1 (en) 2012-11-05
PT3181582T (pt) 2020-03-03
CN105037541A (zh) 2015-11-11
DK2504362T3 (en) 2017-01-30
IL219911A0 (en) 2012-07-31
JP2018080170A (ja) 2018-05-24
KR20120089346A (ko) 2012-08-09
PT2504362T (pt) 2017-01-18
SI2504362T1 (sl) 2017-03-31
SMT202000106T1 (it) 2020-03-13
CY1122674T1 (el) 2021-03-12
KR20190039357A (ko) 2019-04-10
HUE032543T2 (en) 2017-10-30
BR112012012514B1 (pt) 2022-10-04
MX2012006060A (es) 2012-06-19
EP2504362A1 (en) 2012-10-03
EP3670532A1 (en) 2020-06-24
WO2011063980A1 (en) 2011-06-03
RS59955B1 (sr) 2020-03-31
HRP20200241T1 (hr) 2020-06-12
ES2613352T3 (es) 2017-05-24
US20170002067A1 (en) 2017-01-05
US9458233B2 (en) 2016-10-04
EA201200795A1 (ru) 2013-04-30
CN102741283A (zh) 2012-10-17
US8802096B2 (en) 2014-08-12
DK3181582T3 (da) 2020-02-24
US10774136B2 (en) 2020-09-15
JP6591272B2 (ja) 2019-10-16
HUE049376T2 (hu) 2020-09-28
CA2780520A1 (en) 2011-06-03
LT2504362T (lt) 2017-02-10
CN102741283B (zh) 2015-07-15
KR20180034690A (ko) 2018-04-04
RS55571B1 (sr) 2017-05-31
NZ600348A (en) 2014-01-31
EP2504362B1 (en) 2016-11-23
AU2010324141B2 (en) 2014-04-10
LT3181582T (lt) 2020-02-25
PL3181582T3 (pl) 2020-06-01
SMT201700054T1 (it) 2017-03-08
CY1118463T1 (el) 2017-07-12
BR112012012514A2 (pt) 2020-07-28
JP2013512209A (ja) 2013-04-11
SI3181582T1 (sl) 2020-03-31
US20140314772A1 (en) 2014-10-23
JP2016074721A (ja) 2016-05-12
JP2019163266A (ja) 2019-09-26
AU2010324141A1 (en) 2012-06-21
CL2012001304A1 (es) 2012-08-03
US20150266949A1 (en) 2015-09-24
ES2773725T3 (es) 2020-07-14
NL301334I2 (nl) 2025-09-10

Similar Documents

Publication Publication Date Title
SMT201700054B (it) Porzioni leganti anti-c5a con elevata attività bloccante
EP3865162C0 (en) RINSE SYRINGE ASSEMBLY
EP3266489C0 (en) Needle guard
EP2445508A4 (en) NITRIC OXIDE THERAPIES
DK2429477T3 (da) Præstationsforbedring
DK2646149T3 (da) Metalholdig zeolitkatalysator
EP2609148A4 (en) PHTHALIC ACID-FREE SOFT MAKER
FR2969499B3 (fr) Auto-injecteurs
HUE051199T2 (hu) Módosított anti-CD-4 antitestek
EP2378292A4 (en) Autoanalyzer
UY33111A (es) Jeringas
BRPI1011397A2 (pt) atenuador
DOP2011000348A (es) Construcciones casb7439
ATE545328T1 (de) Mähfingeranordnung
BR112012006693A2 (pt) combinação
BR112012006968A2 (pt) combinação
FI20100413A0 (fi) Vuodekokoonpano
BR112013014731A2 (pt) tamavidina modificada
EP2578136A4 (en) DISHWASHER
ES1072470Y (es) Articulacion con medios de bloqueo
ES1070148Y (es) Macolla para barrotes mejorada
DE112010004907A5 (de) Dämpfungseinrichtung
UA21599S (uk) Запальничка
FI8401U1 (fi) Suojus
FR2960134B1 (fr) Protection dorsale